HD
Therapeutic Areas
Curasight Pipeline
| Drug | Indication | Phase |
|---|---|---|
| uTREAT® (177Lu-CUR-N86) | Glioblastoma (Recurrent) | Phase 1/2a |
| uTREAT® | Prostate Cancer | Preclinical |
| uTRACE® (68Ga-CUR-N86) | Diagnostic Imaging (Multiple Solid Tumors) | Phase 2 |
Leadership Team at Curasight
UK
Ulrich Krasilnikoff
Chief Executive Officer & Chief Financial Officer
AK
Andreas Kjær
Chief Scientific Officer, Co-founder
SF
Søren Fabricius
Chief Development Officer
KD
Kirsten Drejer
Chairperson of the Board
MR
Marcel Reichen
Board Member
DC
Dr. Colin Hayward
Board Member